Autier Philippe
International Prevention Research Institute, Strathclyde Institute of Global Public Health at iPRI, 69006 Lyon, France.
Rev Prat. 2013 Dec;63(10):1369-77.
Breast cancer screening in France is done though two parallel systems: individualized screening and a national programme of organized screening. The latter is free of charge and manages a double-reading of mammography films. Since 2004, a steadily greater proportion of French women 50 to 74 years of age participate to the national programme. Justification of screening in France is based on Swedish randomised trials that documented the ability of mammography screening to reduce the risk to die from breast cancer. However, since 3 years, a growing number of studies indicate that screening seems not to have much influence on the incidence of advanced breast cancer and on mortality from breast cancer Moreover, numerous breast cancers are detected that would have never clinically surfaced and would have never been life threatening (overdiagnosis). In view of current doubts, it is better to inform women on health benefits, limitations and possible side effects of mammography screening. For women willing to be screened, it is recommended to invite them to participate to the national programme.
个体化筛查和全国有组织的筛查计划。后者是免费的，并对乳腺钼靶照片进行双重读片。自2004年以来，年龄在50至74岁之间的法国女性参与全国计划的比例稳步上升。法国筛查的依据是瑞典的随机试验，这些试验证明了乳腺钼靶筛查降低死于乳腺癌风险的能力。然而，三年来，越来越多的研究表明，筛查似乎对晚期乳腺癌的发病率和乳腺癌死亡率没有太大影响。此外，检测出了许多原本在临床上不会出现且不会危及生命的乳腺癌（过度诊断）。鉴于目前的疑问，最好告知女性乳腺钼靶筛查的健康益处、局限性和可能的副作用。对于愿意接受筛查的女性，建议邀请她们参加全国计划。
